Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 3,275 shares, a decrease of 77.2% from the May 14th total of 14,337 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 21,621 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Barinthus Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Rangeley Capital LLC grew its stake in shares of Barinthus Biotherapeutics by 88.8% during the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares during the period. Renaissance Technologies LLC grew its stake in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after buying an additional 76,800 shares during the period. Finally, Baird Financial Group Inc. raised its holdings in shares of Barinthus Biotherapeutics by 108.2% in the 2nd quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after purchasing an additional 100,000 shares during the period. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Stock Up 0.6%

Shares of NASDAQ:BRNS opened at $0.72 on Wednesday. The company has a market cap of $29.58 million, a P/E ratio of -0.56 and a beta of -0.40. Barinthus Biotherapeutics has a 52 week low of $0.51 and a 52 week high of $2.92. The business has a fifty day simple moving average of $0.64 and a 200-day simple moving average of $0.67.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.14.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Barinthus Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.